Manufacturer's investigation conclusion: a direct correlation between heartmate 3 left ventricular assist system (lvas), serial number mlp-012780, and the reported gastrointestinal (gi) bleeding, fluid overload, and erythema could not be conclusively determined through this evaluation.It was reported that the patient was admitted on (b)(6) 2020 for fluid overload and decreased hemoglobin.Erythema was also noted around the driveline.The fluid overload was treated with medication for diuresis.Melena was also reported, and a tagged red blood cell study was completed on (b)(6) 2020 with no acute findings.Anticoagulation medication was resumed on (b)(6) 2020 and an intravenous (iv) iron replacement was given.The plan was to trend the patient¿s international normalized ratio (inr) up slowly, and the patient was discharged home on (b)(6) 2020.The patient ultimately expired on 12feb2021 after declining intravenous (iv) antibiotics for an infection, and voluntarily turning the left ventricular assist device (lvad) off after a period of declining health in home hospice (refer to manufacturer report number 2916596-2021-01014).The heartmate 3 left ventricular assist system (lvas) instructions for use (ifu), rev.C is currently available.Section 1 of this document lists bleeding as adverse event that may be associated with the use of the heartmate 3 left ventricular assist system.Section 6 ¿patient care and management¿ (under "anticoagulation") outlines the recommended anticoagulation regimen (including inr range) for patients using the heartmate 3 lvas as well as the suggested anticoagulation modifications in the event that there is a risk of bleeding.The relevant sections of the device history records for mlp-012780 were reviewed and showed no deviations from manufacturing or quality assurance specifications.No further information was provided.The manufacturer is closing the file on this event.
|